Long-term Efficacy of Safinamide on Parkinson's Disease Chronic Pain.

ABSTRACT: INTRODUCTION:Chronic pain is an important yet overlooked non-motor symptom of Parkinson's disease (PD), caused by an imbalance of the dopaminergic and glutamatergic systems. Safinamide has a multimodal mechanism of action, dopaminergic (reversible MAO-B inhibition) and non-dopaminergic (modulation of the abnormal glutamate release), that might be beneficial for both motor and non-motor symptoms. OBJECTIVES:To investigate the long-term (2-year) efficacy of safinamide on PD chronic pain and to confirm the positive effects observed after 6 months of treatment. METHODS:This is a post hoc analysis of the data from the 2-year study 018, focused on the reduction of concomitant pain treatments and on the scores of pain-related items of the Parkinson's disease quality of life questionnaire (PDQ-39)

SUBMITTER: Cattaneo C 

PROVIDER: S-EPMC5910467 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature